论文部分内容阅读
综述可望在近期内成为商品化产品的激素类男性避孕药的临床研究现状。研究结果显示,十一酸睾酮以其长效、能制成口服药品且副作用小而优于庚酸睾酮,极有希望在近期内商品化。皋酮环丁酯效果与十一酸睾酮相当,但需解决配方制剂问题。雄激素与孕激素、雌激素、促性腺激素类似物的联合应用可以提高抑精功效,减少副作用,其中雄激素与促性腺激素拮抗剂为最佳配伍,但成本昂贵无法推广。长效雄激素制剂与长效孕激素的配伍为最可行的方案。
This review summarizes the current status of clinical research on hormonal male contraceptives that are expected to become commercial products in the near future. The results showed that testosterone undecanoate with its long-acting, can be made oral drugs and side effects of small but superior to testosterone enanthate, very promising in the near future commercialization. The effect of ketoprofen butyl ester is comparable to that of testosterone undecanoate, but formulation formulation problems need to be addressed. Combined use of androgens with progesterone, estrogen and gonadotropin analogues can improve the anti-sperm effect and reduce the side effects. Androgen and gonadotropin antagonist are the best compatibility, but the cost is expensive and can not be promoted. Long-acting androgen formulations and long-acting progesterone compatibility is the most feasible solution.